Development of a quantitative vancomycin immunoassay for the Abbott AxSYM analyzer.
A novel fluorescence polarization immunoassay for vancomycin on Abbott AxSYM analyzer is described. The immunoassay allows for the accurate quantification of vancomycin in the presence of the crystalline degradation product (CDP). It displays dilution linearity from 1.0 microg/ml to 100.0 microg/ml, coefficients of variation ranging from 2.94% to 4.26%, recovery from 98% to 105%, and a sensitivity of <2.0 microg/ml. The assay demonstrates no cross-reactivity to crystalline degradation product, and to commonly-prescribed and over-the-counter drugs, as well as a minimum interference from endogenous substances.
Adamczyk
M
M
Abbott Diagnostics Division, Abbott Laboratories, Abbott Park, Illinois 60064, USA.
Brate
E M
EM
Chiappetta
E G
EG
Ginsburg
S
S
Hoffman
E
E
Klein
C
C
Perkowitz
M M
MM
Rege
S D
SD
Chou
P P
PP
Costantino
A G
AG
D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood* / Q000737:chemistry; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D016001:Confidence Intervals; D003460:Crystallization; D004340:Drug Contamination / Q000517:prevention & control; D004347:Drug Interactions; D016903:Drug Monitoring / Q000295:instrumentation / Q000379:methods*; D005260:Female; D016231:Fluorescence Polarization Immunoassay / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D016014:Linear Models; D051379:Mice; D004366:Nonprescription Drugs / Q000737:chemistry; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013056:Spectrophotometry, Ultraviolet; D014640:Vancomycin / Q000097:blood* / Q000737:chemistry
D000900:Anti-Bacterial Agents; D004366:Nonprescription Drugs; D014640:Vancomycin